



Sheet 1 of 1

KFORM PTO 1449 (modified)		Atty. Docket No. X-11965	Serial No 09/647,278
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicants Janet M. Hock, et al.	
		Filing Date September 26, 2000	Group 1646

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
	AA	US			
	AB	US			

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	BA					
	BB					

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T <sup>6</sup>
RLi	CAS	SLOVIK, et al., "Deficient Production of 1,25-Dihydroxyvitamin D in Elderly Ostoporotic Patients," <i>The New England Journal of Medicine</i> , Vol. 305, No. 7, 372-374 (August 13, 1981).	
RLi	CAT	NEER, et al., "Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women With Osteoporosis," <i>The New England Journal of Medicine</i> , Vol. 334, No. 19 (May 10, 2001).	
RLi	CAU	Lilly Research Laboratories, "Teriparatide Injection NDA 21-318; Endocrinologic and Metabolic Drugs Advisory Committee Briefing Document," Volume 1, 1-128 (June 15, 2001).	
	CAV		
	CAW		

Examiner Signature *Ruixiang Li* Date Considered *12/05/2004*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.  
Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.